Bhagirath Dholaria, MD

[Bhagirath Dholaria, MD @DholariaMD]

Innovative trials with focus on #myeloma cure!! @VUMCDiscoveries @VUMChealth

[CoMMit-Myeloma Trial Innovated @CoMMitTrials]

Productive evening conspiring against myeloma. This fantastic group accrued >150 patients in MM treatment trials in 2025. Several key colleagues couldn't make to MCO, will join us next year.

[Bhagirath Dholaria, MD @DholariaMD]

@DeceraClinEdu @MichaelDJain He is the best! A voice of clarify and reason among the fuzzy data and opinions. 🙏

[CoMMit-Myeloma Trial Innovated @CoMMitTrials]

All CoMMit active trials and past research is now in one place. Learn more about and support our work. https://t.co/bgzUu1YNeE

[Bhagirath Dholaria, MD @DholariaMD]

@JanakiramMurali @mmejia91 @SusanBal9 not surprised. We have not found any benefit of dex or toci prophy in ICANS prevention either with CD19 CAR T. Need mechanistic studies first to define pathophysio of delayed NT before we start planning interventions.

[Dr. Cathy Eng @CathyEngMD]

Co-chaired by 🤩@Sonyareid07 #breastcancer and @DholariaMD #leukemia @VUMCDiscoveries

[Bhagirath Dholaria, MD @DholariaMD]

@DrFredLocke @MoffittNews @hiendliu1 @MichaelDJain @freemanlciaraMD @nishihori Congratulations on this milestone🙌

[Bhagirath Dholaria, MD @DholariaMD]

@RahulBanerjeeMD @End_myeloma @bdermanmd @Rfonsi1 As our therapies get better at achieving <10e-6, we will have enough events/power to test these hypothesis. Clearly 2+HRCA is the group where we need better discrimination before de-escalation.

[Bhagirath Dholaria, MD @DholariaMD]

@ChenyuLinMD @VincentRK @RahulBanerjeeMD @Rfonsi1 @TomBmt133 From my limited experience, it seems inferior control arms given rapidly expanding access to CAR and bispecifics. By the time, we open a study, SOC is no longer appropriate for the given population.

[Dr. Cathy Eng @CathyEngMD]

Here is our June @VUMCDiscoveries #youngadultcancer newsletter. #earlyonset #cancer #nationalcancersurvivorsmonth
Link: https://t.co/QTdS0AZ6Rt

@EOAYACoP #AYA #tooyoung #patientcare #advocacy
@DholariaMD @Sonyareid07 @drholowatyj @jordanberlin5 @JJSingleton1 @ARosen380

[Luciano J Costa @End_myeloma]

Patients with standard risk MM treated with QUADs + ASCT, achieving S-MRD negativity and stopping therapy have <10% risk of progression or MRD resurgence in 4 years!

[IACH @TheIACH]

Join us for the upcoming @TheIACH for Nurses:

Outpatient Bi-Specific Therapy Clinic
with Leslie Mader & Bhagirathbhai Dholaria

🗓️Thursday, May 8 2025
⏲️6pm CET

Register for FREE
⬇️⬇️
https://t.co/P4hRfWKQnR

@lesliemader @DholariaMD @Mohty_EBMT

[Bhagirath Dholaria, MD @DholariaMD]

@AshKishtagari @foghorntx @CCR_AACR @VUMChealth Next step ?combo w VEN/HMA

[Bhagirath Dholaria, MD @DholariaMD]

Open and enrolling @VUMCDiscoveries @BipinSavani @EdenBiltibo

[Luciano J Costa @End_myeloma]

Colorado @ColoradoBlood; Alabama @ONealCancerUAB; NY @Columbia @rajshekharucms; Tennesse @ Vanderbilt @DholariaMD ; Wisconsin @MedicalCollege @bhemato and Madison @nsc_natalie; Washington @fredhutch @RahulBanerjeeMD @DimaDanai ; Oregon @OHSUKnight R. Silberman and E. Medvedova.

[Bhagirath Dholaria, MD @DholariaMD]

@RahulBanerjeeMD @HiraSMian Mostly true in USA at this point. There may be few new candidates on horizon.

[Bhagirath Dholaria, MD @DholariaMD]

@bdermanmd @End_myeloma I have noticed this pattern too in last 3-4 yrs. Many requiring steroids. Also, 3 cases of severe auto-GVHD (bx proven) involving skin+ gut. Not sure if there is a pattern here.

[Bhagirath Dholaria, MD @DholariaMD]

@MediHumdani donor original T LGL. I have a few who recovered ANC with FK taper, rest needed low dose steroid/MTX.

[IACH @TheIACH]

📢 Don't miss the next @TheIACH post #ASH24 webinar:

the Most Important Cellular Therapy Studies
🎙️ Speaker: Dr. Bhagirathbhai Dholaria

🗓️ Friday, January 17, 2025
🕔 5 PM CET

🎟️ Register for FREE:
👉 https://t.co/H3BZLB0Auy

@DholariaMD @Mohty_EBMT

[Bhagirath Dholaria, MD @DholariaMD]

@MediHumdani Bi-specifics are currently at a stage where CAR T therapy was in early 2000. They will outpace CAR given ease of logistics, and combinations.

[Narendra Modi @narendramodi]

Historic and exemplary!

Congratulations to Gukesh D on his remarkable accomplishment. This is the result of his unparalleled talent, hard work and unwavering determination.

His triumph has not only etched his name in the annals of chess history but has also inspired millions of young minds to dream big and pursue excellence.

My best wishes for his future endeavours. @DGukesh